The content of this presentation does not constitute a promise or statement regarding the future performance of the Company. Certain information and conclusions contained herein are related to business prospects, estimate of the Company's operating and financial results and growth prospects.
This information is based on projections related to the Company's management expectations regarding the future of the business and considerations depend on market conditions, regulatory approval, industry performance, exchange rate fluctuations and other risks described in the Company's reports.
Certain percentages and other values included this document have been rounded to make its presentation easier and chart scales can have different proportions, also to make ease of viewing. Therefore, the numbers and graphs generated may not represent an arithmetic sum and may differ from those presented in financial statements.
This presentation does not constitute an offer or solicitation to purchase shares or any other real estate assets of the Company. The presentation or any information contained herein is not to be used on the basis of a contract or commitment.
The information contained herein is informative and should be understood as such.
2
Net Revenue and
Exclusive agreement
Biopharmaceutical
plant certification
Market Share
Ustequinumabe
GMP
HIGHLIGHTS
Earnings Presentation
GLARGINE INSULIN TOTAL MARKET
2Q23
BI UI
1,4
1,2
1
0,8
0,6
0,4
0,2
0
BIOMM +119%
Market +5%
0.603
BIOMM +216%
Market +11%
1.181
1.308
0.636
2Q22
2Q23
6M22
6M23
LILLY
26%
25%
27%
26%
SANOFI
63%
51%
65%
51%
BIOMM
11%
24%
8%
23%
Source: IQVIA
Period 6M = January a June
4
Earnings Presentation
TRASTUZUMABE PRIVATE MARKET 440MG
2Q23
BIOMM +52%
Market +7%
45
40
35
BIOMM +54%
42,336
39,475
Units
30
Market +11%
25
19,593
17,723
20
15
10
5
0
2Q22
2Q23
6M22
6M23
ROCHE
20%
15%
26%
15%
AMGEN
16%
13%
12%
14%
PFIZER
2%
2%
3%
2%
LIBBS
47%
43%
45%
44%
BIOMM
15%
21%
14%
20%
ORGANON
0%
6%
0%
5%
Source: IQVIA
Period 6M = January a June
5
Attachments
Original Link
Original Document
Permalink
Disclaimer
BIOMM SA published this content on 10 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 August 2023 13:00:02 UTC.
Biomm SA, formerly Savicevic Participacoes SA, is a Brazil-based company primarily engaged in the biotechnology industry. The Company is principally engaged in the development and licensing of technology for the production of human insulin and other recombinant proteins. The Companyâs technology is suitable for the production of therapeutic proteins, which are used in the production of drugs and biopharmaceuticals. The Companyâs technology for insulin production is protected by patents in various countries in Europe, Asia, North and South America. In addition, it is active in the development of production process of enzymes that are used in the hydrolysis of biomass and in the manufacture of bio-fuel. As of December 31, 2011, the Companyâs subsidiaries were Biomm International Inc, Biomm Middle East Inc and Biomm Russia Ltd.
BIOMM S.A. 
